Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2010, Vol. 15 ›› Issue (6): 656-662.
Previous Articles Next Articles
LI Guo-fu1,2, YANG Jin1, ZHANG Xue-ying1, ZHAO Hao-ru2
Received:
2010-02-26
Revised:
2010-06-06
Online:
2010-06-26
Published:
2020-09-16
CLC Number:
LI Guo-fu, YANG Jin, ZHANG Xue-ying, ZHAO Hao-ru. Physiologically based gastrointestinal models for the prediction of oral drug absorption[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(6): 656-662.
[1] Dokoumetzidis A,Valsami G,Macheras P. Modelling and simulation in drug absorption processes [J]. Xenobiotica,2007,37(10/11):1052-1065. [2] Willmann S,Schmitt W,Keldenich J,et al. A physiologic model for simulating gastrointestinal flow and drug absorption in rats [J]. Pharm Res,2003,20(11):1766-1771. [3] Willmann S,Schmitt W,Keldenich J,et al. A physiological model for the estimation of the fraction dose absorbed in humans [J]. J Med Chem,2004,47(16):4022-4031. [4] Willmann S,Edginton AN,Dressman JB. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys [J]. Pharm Res,2007,24(7):1275-1282. [5] Troutman MD,Thakker DR. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium [J]. Pharm Res,2003,20(8):1210-1224. [6] Huang W,Lee SL,Yu LX. Mechanistic approaches to predicting oral drug absorption [J]. AAPS J,2009,11(2):217-224 [7] Willmann S,Lippert J,Sevestre M,et al. PK-Sim·: a physiologically based pharmacokinetic 'whole-body' model [J]. Biosilico,2003,1(4):121-124. [8] Yu LX,Llipka E,Crison JR,et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption [J]. Adv Drug Deliv Rev,1996,19(3):359-376. [9] Yu LX. An integrated model for determining causes of poor oral drug absorption [J]. Pharm Res, 1999,16(12):1883-1887. [10] Kortejä rvi H,Urtti A,Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates [J]. Eur J Pharm Sci,2007,30(2):155-166. [11] Tubic M,Wagner D,Spahn-Langguth H,et al. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect [J]. Pharm Res,2006,23(8):1712-1720. [12] Löbenberg R,Krämer J,Shah VP,et al. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide[J]. Pharm Res,2000,17(4):439-444. [13] Okumu A,DiMaso M,Löbenberg R,et al. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug [J]. Pharm Res,2008,25(12):2778-2785. [14] Tubic-Grozdanis M,Bolger MB,Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds [J]. AAPS J,2008,10(1):213-226. [15] Wei H, Dalton C, Maso MD,et al. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption [J]. Eur J Pharm Biopharm,2008,69(3):1046-1056. [16] Jones HM,Parrott N,Ohlenbusch G,et al. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling [J]. Clin Pharmacokinet,2006,45(12):1213-1226. [17] Sawamoto T,Haruta S,Kurosaki Y,et al. Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and abs orbability [J]. J Pharm Pharmacol,1997,49(4) : 450-457. [18] Bohets H,Annaert P,Mannens G,et al. Strategies for absorption screening in drug discovery and development [J]. Curr Top Med Chem,2001,1(5):367-383. [19] Kimura T,Higaki K. Gastrointestinal transit and drug absorption [J]. Biol Pharm Bull, 2002,25(2):149-164. [20] Yokoe J,Iwasaki N,Haruta S,et al. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model [J]. J Control Release,2003,86(2):305-313. [21] Kimura T,Iwasaki N,Yokoe JI,et al. Analysis and prediction of absorption profile including hepatic first-pass metabolism of n-methyltyramine, a potent stimulant of gastrin release present in beer, after oral ingestion in rats by gastrointestinal-transit-absorption model [J]. Drug Metab Dispos,2000,28(5):577-581. [22] Fujioka Y,Kadono K,Fujie Y,et al. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study [J]. J Control Release,2007,119(2):222-228. [23] Dong JQ,Chen B,Gibbs MA,et al. Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration [J]. Expert Opin Drug Metab Toxicol,2007,3(4):491-505. [24] Dokoumetzidis A,Kalantzi L,Fotaki N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models [J]. Expert Opin Drug Metab Toxicol,2007,3:491-505. [25] Jamei M,Turner D,Yang J,et al. Population-based mechanistic prediction of oral drug absorption [J]. AAPS J,2009,11(2):225-237. [26] Jamei M,Marciniak S,Feng K,et al. The Simcyp · population-based ADME simulator [J]. Expert Opin Drug Metab Toxicol,2009,5(2):211-223. [27] 汪音,杨劲,傅继华,等. 基于体外模型数据模拟和预测人体内群体药代参数 [J]. 中国临床药理学与治疗学,2008,13(5):545-551. [28] Kadono K,Yokoe J,Ogawara K,et al. Analysis and prediction of absorption behavior for theophylline orally administered as powders based on gastrointestinal-transit-absorption (GITA) model [J]. Drug Metab Pharmacokinet,2002,17(4):307-315. [29] Ito K,Kusuhara H,Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach [J]. Pharm Res,1999,16(2):225-231. [30] Tam D,Tirona RG,Pang KS. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption [J]. Drug Metab Dispos,2003,31(4):373-383. |
[1] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
[2] | LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130. |
[3] | WANG Fei, HANG Yongfu, WANG Wei. Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048. |
[4] | HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535. |
[5] | LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474. |
[6] | YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177. |
[7] | YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990. |
[8] | DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651. |
[9] | LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang. Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273. |
[10] | WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286. |
[11] | HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69. |
[12] | LIU Chang, DENG Kunhong, HUANG Jie, YANG Shuang, YANG Xiaoyan, XIANG Yuxia, HUANG Lu, ZHANG Zeyu, LIANG Wenzhong, LAN Jing, YANG Guoping. Bioequivalence of moxifloxacin hydrochloride tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1393-1399. |
[13] | HAN Guijuan, JIANG Ji, OUYANG Weiwei, LUO Hong, ZHANG Xiaojun, WANG Minghua. Absorption and excretion of CT-707 in healthy male subjects studied by radioisotope tracer method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1407-1412. |
[14] | LI Na, HAN Hongcan, WANG Jun. General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425. |
[15] | ZHANG Miao, LIU Qian, YAO Xueting, LIU Dongyang. Exploration of early food effect study of innovative drugs based on physiologically-based pharmacokinetic absorption model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1426-1429. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||